Kobayashi Tsunehiro, Arefanian Hossein, Harb George, Tredget Eric B, Rajotte Ray V, Korbutt Gregory S, Rayat Gina R
Surgical-Medical Research Institute, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.
Cell Transplant. 2008;17(10-11):1243-56. doi: 10.3727/096368908787236602.
Several studies have demonstrated that in vitro culture of islets prolonged islet graft survival in immune-competent mice without administration of antirejection drugs. However, we recently showed that in vitro cultured microencapsulated neonatal porcine islets (NPI) were rejected in immune-competent mice not receiving antirejection therapy. The aim of this study was to determine whether culture of microencapsulated NPI in vivo could promote long-term survival of microencapsulated NPI in immune-competent mice without administration of antirejection drugs. Microencapsulated NPI that were cultured in vitro for 7 and 50 days or transplanted initially in immune-deficient C.B.-17 SCID-BEIGE mice for 100 days (in vivo cultured) were characterized and transplanted into streptozotocin-induced diabetic immune-competent BALB/c mice. Day 50 in vitro cultured and day 100 in vivo cultured microencapsulated NPI showed significantly higher insulin and DNA content, indicating maturation of NPI compared to day 7 in vitro cultured microencapsulated NPI. Interestingly, in vivo cultured microencapsulated NPI expressed lower levels of porcine antigens compared to day 7 and day 50 in vitro cultured microencapsulated NPI. Transplantation of day 7 in vitro cultured microencapsulated NPI did not reverse diabetes in immune-competent BALB/c mouse recipients. In contrast, transplantation of day 50 in vitro cultured and in vivo cultured microencapsulated NPI into diabetic immune-competent BALB/c mice resulted in the immediate reversal of hyperglycemia within 2 days posttransplantation. However, all recipients of day 50 in vitro cultured microencapsulated NPI eventually rejected their grafts by day 15 posttransplantation, while 6 of 10 BALB/c mouse recipients of in vivo cultured microencapsulated NPI maintained normoglycemia for 100 days posttransplantation. These results show that in vivo culture of NPI in immune-deficient mice results in the modulation of NPI, which allows for their long-term survival in immune-competent mice without antirejection therapy.
多项研究表明,在不使用抗排斥药物的情况下,胰岛的体外培养可延长其在免疫健全小鼠体内的移植存活时间。然而,我们最近发现,在未接受抗排斥治疗的免疫健全小鼠中,体外培养的微囊化新生猪胰岛(NPI)会被排斥。本研究的目的是确定在体内培养微囊化NPI是否能在不使用抗排斥药物的情况下,促进其在免疫健全小鼠体内长期存活。对在体外培养7天和50天的微囊化NPI,或最初在免疫缺陷的C.B.-17 SCID-BEIGE小鼠体内培养100天(体内培养)的微囊化NPI进行特性分析后,将其移植到链脲佐菌素诱导的糖尿病免疫健全BALB/c小鼠体内。与体外培养7天的微囊化NPI相比,体外培养50天和体内培养100天的微囊化NPI的胰岛素和DNA含量显著更高,表明NPI已成熟。有趣的是,与体外培养7天和50天的微囊化NPI相比,体内培养的微囊化NPI表达的猪抗原水平更低。将体外培养7天的微囊化NPI移植到免疫健全的BALB/c小鼠受体中,并未逆转糖尿病。相反,将体外培养50天和体内培养的微囊化NPI移植到糖尿病免疫健全的BALB/c小鼠体内,移植后2天内血糖立即恢复正常。然而,所有接受体外培养50天的微囊化NPI移植的受体最终在移植后15天排斥了移植物,而10只接受体内培养微囊化NPI移植的BALB/c小鼠中有6只在移植后100天维持血糖正常。这些结果表明,在免疫缺陷小鼠体内培养NPI会导致NPI发生调节,从而使其在不进行抗排斥治疗的情况下,能在免疫健全小鼠体内长期存活。